Health ❯ Healthcare ❯ Medications

Weight Loss

GLP-1 Drugs Mounjaro Wegovy Ozempic GLP-1 Agonists GLP-1 Receptor Agonists GLP-1 Orforglipron Semaglutide Side Effects

UK Regulator Approves Eli Lilly’s Foundayo Tablet for Weight Loss and Type 2 Diabetes

The MHRA’s authorisation allows private prescriptions now, with NHS funding subject to a NICE cost‑effectiveness review.

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Wegovy Pill Arrives in UK Private Market as Clinicians Flag Dosing and Safety Risks

Wegovy Pill Hits UK Private Market as Safety and Access Worries Rise

GLP‑1 Use Reaches 11% of U.S. Adults as New Evidence Spurs Policy and Safety Scrutiny

Wegovy Pill Approved, Private Sales Start in UK

Medicare Launches GLP‑1 Bridge to Offer Select Weight‑Loss Drugs for $50 a Month

New Studies Find Less Movement and Behavioral Signals in GLP‑1 Weight‑loss Users

MHRA Approves Wegovy Weight‑Loss Tablet as Private Demand Soars

New Data Show Lower Activity, Muscle Loss and Mood Changes Linked to GLP‑1 Weight Drugs

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Samsung and MGH Launch Trial Using Galaxy Watch to Track Muscle Loss on GLP‑1 Therapy

Oral GLP‑1 Approval and New Trials Push Weight‑Loss Drugs Into Mass Market

UK Regulators Approve Single-Dose 7.2mg Wegovy Pen for Weekly Use

France’s Weight-Loss Drug Boom Spurs Shortages, Safety Alerts, and a Shadow Market

Doctor Warns GLP‑1 Weight‑Loss Shots Can Reduce Bone Density

Germany Keeps GLP-1 Weight-Loss Drugs Off Statutory Coverage

Stiftung Warentest Backs Only Mounjaro and Wegovy for Durable Weight Loss

GLP-1 Weight-Loss Boom Is Reshaping Diets as Experts Urge Lifestyle Support

Private GLP-1 Weight-Loss Use in UK Skews to Middle-Class Women, Analysis Shows